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Introduction {#sec005}
============

Type 2 diabetes (T2DM), a complex metabolic disorder, has major health, social and economic consequences. Globally, China has the largest T2DM epidemic. Currently, around 114 million (11%) adults are living with T2DM, which is expected to rise to 120 million by 2045 \[[@pone.0220047.ref001]\].

Ningbo, an economically developed city, is located in the northeast Zhejiang province of China. In 2015, the T2DM prevalence in adults over 40 years of age in Ningbo was 21% \[[@pone.0220047.ref002]\]. At a tertiary care department (Department of Endocrinology and Metabolism, Ningbo First Hospital), more than 50% of T2DM patients receiving treatment had poor glycaemic control and vascular complications \[[@pone.0220047.ref003]\]. The study was conducted at Ningbo First Hospital. This is a tertiary care hospital (with 1600 beds), which is primarily responsible for delivering specialist health services and for performing a larger role in medical education and research \[[@pone.0220047.ref004],[@pone.0220047.ref005]\]. Nationals (including T2DM patients) can visit any Chinese hospital of their choice and is not based on a referral system by the general practitioners. Thus, this hospital is visited by local people, as well as those from surrounding areas \[[@pone.0220047.ref004]\].

The concurrent prescription or usage of multiple medicines is known as polypharmacy \[[@pone.0220047.ref006]\]. Polypharmacy can lead to interactions between drugs and results in adverse drug events \[[@pone.0220047.ref007]--[@pone.0220047.ref009]\]. It can have a negative effect on the T2DM patient, their family/carer, the health system and the economy. In patients, it can adversely affect their adherence to medicines, quality of life and life expectancy, can lead to suboptimal blood glucose control and hospital admissions, and can increase severe hypoglycaemia risk and healthcare costs \[[@pone.0220047.ref010]--[@pone.0220047.ref014]\]. Studies conducted in different diabetes (including T2DM) populations and settings have reported a range of polypharmacy prevalence figures (6--85%) \[[@pone.0220047.ref015]--[@pone.0220047.ref024]\].

Until now, no research has been conducted to explore polypharmacy prescription among T2DM patients at this tertiary care department. The study objectives were to determine the prevalence of polypharmacy prescription among T2DM patients at this tertiary care department and to determine factors that independently predict this polypharmacy prescription. The knowledge of the prevalence of polypharmacy prescription and factors associated with their polypharmacy prescription could be used by Chinese and/or international experts in developing, evaluating and implementing interventions for supporting medicines optimisation (and deprescribing) in Ningbo and beyond in China.

Materials and methods {#sec006}
=====================

Study design, data source and period {#sec007}
------------------------------------

The 5-year study period was from 1 July 2012 to 30 June 2017. An existing computerised medical records database was used in conducting a retrospective cross-sectional study. The database includes information on all patients from their admission to discharge, including their socio-demographic and behavioural information, medical and surgical history, diagnostics (including laboratory results) and prescribed medicines. As this is a medical records database, the medico-nursing team is responsible for data entry on to the database. Another independent team of hospital staff checks the quality of the data and is responsible for the overall management of the database. On our request and with permission from the Research Ethics Committee at the Ningbo First Hospital, China, the data were extracted from the database by a dedicated engineer.

Study population, inclusion and exclusion criteria {#sec008}
--------------------------------------------------

The study included adult (≥18 years of age) T2DM inpatients who were discharged from the tertiary care department for the first time during the study period. If a patient had more than one hospitalisation during the study period, only data relevant to the index event (ie, first hospitalisation) were extracted. Although the database includes information on all inpatients from their admission to discharge, we extracted the prescription data at the time of discharge, as medicines were prescribed as part of their long-term treatment plan. The study excluded those diagnosed with type 1 diabetes, secondary diabetes, gestational diabetes, unknown type of diabetes or endocrine diseases (such as hyperthyroidism and Cushing syndrome).

Study variables {#sec009}
---------------

We extracted the following independent variables from the database: age (18--39 years (younger age), 40--59 years (middle age) or ≥60 years (older age)) \[[@pone.0220047.ref025]\], sex (male or female), education (university/college, class 7--12, class 1--6 or no qualifications), occupation (manual workers (ie, more physical than mental work), non-manual workers (ie, more mental than physical work) or never worked/retired), marital status (married or single/divorced/widowed), residence (urban or rural based on the "hukou" system (ie, residence registration system in China)) \[[@pone.0220047.ref026]\], health insurance, smoking (current status), alcohol drinking (current status), duration of T2DM (≤1 year, \>1--5 years, \>5--10 years or \>10 years), blood glucose level (glycated haemoglobin (HbA1c)---\<7% (good) or ≥7% (poor)) \[[@pone.0220047.ref027]\]; estimated using the high-performance liquid chromatographic (HPLC) method, using the D-10 Hemoglobin Analyzer (Bio-Rad, USA)), length of hospital stay (≤5 days, \>5--10 days or \>10 days) and comorbidities (ie, ≥1 comorbidities and were coded using the International Statistical Classification of Diseases, 10^th^ revision (ICD-10)) \[[@pone.0220047.ref028]\]. The dependent variable extracted was prescribed medicines at discharge, which were coded using the World Health Organization's Anatomical Therapeutic and Chemical (ATC) Classification \[[@pone.0220047.ref029]\]. A polypill was counted as a single medicine. Polypharmacy prescription was defined as the simultaneous prescription of ≥5 medicines by the clinician at the time of discharge for daily usage by the patient as part of his/her long-term treatment plan \[[@pone.0220047.ref017],[@pone.0220047.ref030],[@pone.0220047.ref031]\].

Ethics {#sec010}
------

Ethics approval was obtained from the Research Ethics Committee at the Ningbo First Hospital, China. The authors had no access to information that could identify individual participants during data analysis. Therefore, as per the research ethics rules, no informed consent was necessary.

Statistical analyses {#sec011}
--------------------

Over a 5-year period, amongst T2DM patients, the prevalence of polypharmacy prescription was calculated. Numbers and proportions were calculated for categorical variables. Means and standard deviations (SDs) were calculated for normally distributed continuous variables. Simple logistic regression method was used to explore the relationship between independent variables and polypharmacy prescription. To find any independent relationship, multiple logistic regression models were developed using backward stepwise regression analyses and we included all the independent variables. We also carried out sensitivity analyses--in multiple logistic regression models, only those independent variables with a p-value of ≤0.20 in simple logistic regressions were included. We calculated Odds ratios (ORs) and their respective 95% confidence intervals (CIs). IBM SPSS Statistics Version 20.0 for Windows was used for data analysis. In addition, we carried out logistic regression analyses to explore the association between neoplasms (no, benign and malignant) and polypharmacy prescription.

Results {#sec012}
=======

The study inclusion criteria were satisfied by 3370 T2DM patients. The mean (±SD) age of T2DM patients was 62.9 (±13.8) years and around 51% (n = 1713) of them were male. Over a 5-year period, amongst T2DM patients, the prevalence of polypharmacy prescription was 72.2% (n = 2432). [Fig 1](#pone.0220047.g001){ref-type="fig"} shows the number of medicines that were prescribed in our study. Those who were prescribed polypharmacy, the mean (± SD) number of comorbidities and medicines were 5 (±2) and 8 (±2), respectively.

![Number of prescribed medicines in our study.](pone.0220047.g001){#pone.0220047.g001}

[Table 1](#pone.0220047.t001){ref-type="table"} shows the most common medicines which were prescribed in our study. 96.7% of T2DM patients were on antidiabetic agents (79.8% were on oral antidiabetic drugs and 74.8% were on insulin), 36.9% were on antithrombotic agents and 69.5% were on lipid modifying agents.

10.1371/journal.pone.0220047.t001

###### Most commonly prescribed medicines in our study.

![](pone.0220047.t001){#pone.0220047.t001g}

  -----------------------------------------------------------------------------------------------------------------------
  Classification of medicines (based on ATC classification)                                              Number of\
                                                                                                         T2DM patients\
                                                                                                         n(%)
  ------------------------------------------------------------------------------------------------------ ----------------
  ***Alimentary tract and metabolism (A)***                                                              3312(98.3)

  **Drugs used in diabetes (A10)**                                                                       3258(96.7)

  **Blood glucose lowering drugs, excl. insulins (A10B)**                                                2688(79.8)

  Alpha glucosidase inhibitors (A10BF)                                                                   1948(57.8)

  Biguanides (A10BA)                                                                                     1651(49.0)

  Repaglinide/nateglinide (A10BX02, A10BX03)                                                             476(14.1)

  Sulfonamides (A10BB)                                                                                   286(8.5)

  Thiazolidinediones (A10BG)                                                                             71(2.1)

  **Insulin and analogues (A10A)**                                                                       2520(74.8)

  Insulins and analogues for injection, intermediate/long-acting (A10AC, A10AE)                          1841(54.6)

  Insulins and analogues for injection, fast-acting\                                                     1251(37.1)
  (A10AB)                                                                                                

  Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)   672(19.9)

  **Drugs for acid related disorders (A02)**                                                             699(20.7)

  Proton pump inhibitors (A02BC)                                                                         662(19.6)

  ***Cardiovascular system (C)***                                                                        2790(82.8)

  **Lipid modifying agents (C10)**                                                                       2343(69.5)

  HMG CoA reductase inhibitors (C10AA)                                                                   2174(64.5)

  Atorvastatin and amlodipine (C10BX03)                                                                  49(1.5)

  **Agents acting on the renin-angiotensin-aldosterone system (C09)**                                    1640(48.7)

  Angiotensin II antagonists and calcium channel blockers (C09DB)                                        537(15.9)

  Angiotensin II antagonists and diuretics (C09DA)                                                       161(4.8)

  **Calcium channel blockers (C08)**                                                                     483(14.3)

  **Beta blocking agents (C07)**                                                                         386(11.5)

  **Diuretics (C03)**                                                                                    254(7.5)

  **Cardiac therapy (C01)**                                                                              245(7.3)

  ***Blood and blood forming organs (B)***                                                               1789(53.1)

  **Antithrombotic agents (B01)**                                                                        1244(36.9)

  Acetylsalicylic acid (B01AC06)                                                                         1030(30.6)

  ***Nervous system (N)***                                                                               385(11.4)

  ***Musculoskeletal system (M)***                                                                       283(8.4)

  ***Anti-infectives for systemic use(J)***                                                              281(8.3)

  ***Genitourinary system and sex hormones (G)***                                                        204(6.1)

  ***Respiratory system (R)***                                                                           151(4.5)
  -----------------------------------------------------------------------------------------------------------------------

[Table 2](#pone.0220047.t002){ref-type="table"} shows the characteristics of T2DM patients with and without polypharmacy prescription. The polypharmacy prescription was found to be associated with age, education, occupation, residence, health insurance, duration of T2DM (\>5 years), blood glucose level, length of hospital stay and commodities like neoplasm, other endocrine, nutritional and metabolic diseases, nervous system diseases, circulatory system diseases, skin and subcutaneous tissue diseases, musculoskeletal system and connective tissue diseases, genitourinary system diseases and during pregnancy, childbirth and the puerperium.

10.1371/journal.pone.0220047.t002

###### Characteristics of T2DM patients with and without polypharmacy prescription.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                     Total (3370)   Polypharmacy prescription\   Polypharmacy\   Unadjusted OR (95% CI)
                                                                                                                    No (938)\                    prescription\   
                                                                                                                    n(%)                         Yes (2432)\     
                                                                                                                                                 n(%)            
  -------------------------------------------------------------------------------------------------- -------------- ---------------------------- --------------- ------------------------
  **Age (in years)**                                                                                                                                             

  18--39                                                                                             205            141(68.8)                    64(31.2)        1

  40--59                                                                                             1043           393(37.7)                    650(62.3)       3.64(2.64,5.02)

  ≥60                                                                                                2122           404(19.0)                    1718(81.0)      9.37(6.84,12.83)

  **Sex**                                                                                                                                                        

  Male                                                                                               1713           474(27.7)                    1239(72.3)      1

  Female                                                                                             1657           464(28.0)                    1193(72.0)      0.98(0.85,1.14)

  **Education**                                                                                                                                                  

  University/college                                                                                 352            142(40.3)                    210(59.7)       1

  Class 7--12                                                                                        1322           400(30.3)                    922(69.7)       1.56(1.22,1.99)

  Class 1--6                                                                                         1144           270(23.6)                    874(76.4)       2.19(1.70,2.82)

  No qualifications                                                                                  552            126(22.8)                    426(77.2)       2.29(1.71,3.06)

  **Occupation**                                                                                                                                                 

  Manual workers                                                                                     727            211(29.0)                    516(71.0)       1

  Non-manual workers                                                                                 771            319(41.4)                    452(58.6)       0.58(0.47,0.72)

  Never worked/retired                                                                               1872           408(21.8)                    1464(78.2)      1.47(1.21,1.78)

  **Marital status**                                                                                                                                             

  Married                                                                                            2895           822(28.4)                    2073(71.6)      1

  Single/divorced/widowed                                                                            475            116(24.4)                    359(75.6)       1.23(0.98,1.54)

  **Residence**                                                                                                                                                  

  Urban                                                                                              1988           506(25.5)                    1482(74.5)      1

  Rural                                                                                              1382           432(31.3)                    950(68.7)       0.75(0.65,0.87)

  **Health insurance**                                                                                                                                           

  Yes                                                                                                2882           749(26.0)                    2133(74.0)      1

  No                                                                                                 488            189(38.7)                    299(61.3)       0.56(0.46,0.68)

  **Smoking (current status)**                                                                                                                                   

  No                                                                                                 2713           756(27.9)                    1957(72.1)      1

  Yes                                                                                                657            182(27.7)                    475(72.3)       1.01(0.83,1.22)

  **Alcohol drinking (current status)**                                                                                                                          

  No                                                                                                 3005           845(28.1)                    2160(71.9)      1

  Yes                                                                                                365            93(25.5)                     272(74.5)       1.14(0.89,1.47)

  **Duration of T2DM (in years)**                                                                                                                                

  ≤1                                                                                                 140            66(47.1)                     74(52.9)        1

  \>1--5                                                                                             780            346(44.4)                    434(55.6)       1.12(0.78,1.61)

  \>5--10                                                                                            746            227(30.4)                    519(69.6)       2.04(1.41,2.94)

  \>10                                                                                               1704           299(17.5)                    1405(82.5)      4.19(2.94,5.97)

  **Blood glucose level (HbA1c)**                                                                                                                                

  \<7%                                                                                               603            221(36.7)                    382(63.3)       1

  ≥7%                                                                                                2678           684(25.5)                    1994(74.5)      1.69(1.40,2.03)

  Unknown                                                                                            89             33(37.1)                     56(62.9)        0.98(0.62,1.56)

  **Length of hospital stay (in days)**                                                                                                                          

  ≤5                                                                                                 374            201(53.7)                    173(46.3)       1

  \>5--10                                                                                            1815           502(27.7)                    1313(72.3)      3.04(2.42,3.82)

  \>10                                                                                               1181           235(19.9)                    946(80.1)       4.68(3.65,6.00)

  **Comorbidities**                                                                                                                                              

  **Infectious and parasitic diseases (A00-B99)**                                                                                                                

  No                                                                                                 3048           846(27.8)                    2202(72.2)      1

  Yes                                                                                                322            92(28.6)                     230(71.4)       0.96(0.75,1.24)

  **Neoplasms (C00-D48)**                                                                                                                                        

  No                                                                                                 3157           844(26.7)                    2313(73.3)      1

  Yes                                                                                                213            94(44.1)                     119(55.9)       0.46(0.35,0.61)

  **Blood diseases and certain disorders involving the immune mechanism (D50-D89)**                                                                              

  No                                                                                                 3271           909(27.8)                    2362(72.2)      1

  Yes                                                                                                99             29(29.3)                     70(70.7)        0.93(0.60,1.44)

  **Endocrine, nutritional and metabolic diseases (E00-E90)**[\*](#t002fn001){ref-type="table-fn"}                                                               

  No                                                                                                 449            220(49.0)                    229(51.0)       1

  Yes                                                                                                2921           718(24.6)                    2203(75.4)      2.95(2.41,3.61)

  **Mental and behavioural disorders (F00-F99)**                                                                                                                 

  No                                                                                                 3275           919(28.1)                    2356(71.9)      1

  Yes                                                                                                95             19(20.0)                     76(80.0)        1.56(0.94,2.59)

  **Nervous system diseases (G00-G99)**                                                                                                                          

  No                                                                                                 3159           895(28.3)                    2264(71.7)      1

  Yes                                                                                                211            43(20.4)                     168(79.6)       1.54(1.10,2.18)

  **Circulatory system diseases (I00-I99)**                                                                                                                      

  No                                                                                                 1210           608(50.2)                    602(49.8)       1

  Yes                                                                                                2160           330(15.3)                    1830(84.7)      5.60(4.76,6.59)

  **Respiratory system diseases (J00-J99)**                                                                                                                      

  No                                                                                                 2908           824(28.3)                    2084(71.7)      1

  Yes                                                                                                462            114(24.7)                    348(75.3)       1.21(0.96,1.51)

  **Digestive system diseases (K00-K93)**                                                                                                                        

  No                                                                                                 1800           510(28.3)                    1290(71.7)      1

  Yes                                                                                                1570           428(27.3)                    1142(72.7)      1.06(0.91,1.23)

  **Skin and subcutaneous tissue diseases (L00-L99)**                                                                                                            

  No                                                                                                 3214           909(28.3)                    2305(71.7)      1

  Yes                                                                                                156            29(18.6)                     127(81.4)       1.73(1.15,2.60)

  **Musculoskeletal system and connective tissue diseases (M00-M99)**                                                                                            

  No                                                                                                 2639           807(30.6)                    1832(69.4)      1

  Yes                                                                                                731            131(17.9)                    600(82.1)       2.02(1.64,2.48)

  **Genitourinary system diseases (N00-N99)**                                                                                                                    

  No                                                                                                 2501           719(28.7)                    1782(71.3)      1

  Yes                                                                                                869            219(25.2)                    650(74.8)       1.20(1.01,1.43)

  **Pregnancy, childbirth and the puerperium (O00-O99)**                                                                                                         

  No                                                                                                 3336           905(27.1)                    2431(72.9)      1

  Yes                                                                                                34             33(97.1)                     1(2.9)          0.01(0.00,0.08)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Excludes T2DM

[Table 3](#pone.0220047.t003){ref-type="table"} shows the multiple backward stepwise logistic regression analyses--all the independent variables were included. The odds of polypharmacy prescription increased with patients' age (18--39 years: 1; 40--59 years: OR 1.86, 95% CI 1.28--2.71; and ≥60 years: 2.42, 1.65--3.55), duration of T2DM (≤1 year: 1; \>5--10 years: 1.70, 1.10--2.62; and \>10 years: 2.55, 1.68--3.89), and length of hospital stay (≤5 days: 1; \>5--10 days: 2.43, 1.86--3.17; and \>10 days: 2.99, 2.24--3.99), and were higher in those with poor blood glucose level (2.09, 1.67--2.62) and with comorbidities like other endocrine, nutritional and metabolic diseases (2.24, 1.76--2.85), circulatory system diseases (4.35, 3.62--5.23), skin and subcutaneous tissue diseases (1.64, 1.04--2.59), and musculoskeletal system and connective tissue diseases (1.61, 1.27--2.03). The odds of polypharmacy prescription were lower in those with comorbidities like neoplasms (0.51, 0.36--0.70) and during pregnancy, childbirth and the puerperium (0.06, 0.01--0.49).

10.1371/journal.pone.0220047.t003

###### Multiple backward stepwise logistic regression analyses to determine factors independently associated with polypharmacy prescription---all the independent variables were included.

![](pone.0220047.t003){#pone.0220047.t003g}

                                                                                                     Adjusted OR (95% CI)
  -------------------------------------------------------------------------------------------------- ----------------------
  ***Polypharmacy prescription (Yes)***                                                              
  **Age (in years)**                                                                                 
  18--39                                                                                             1
  40--59                                                                                             1.86(1.28,2.71)
  ≥60                                                                                                2.42(1.65,3.55)
  **Duration of T2DM (in years)**                                                                    
  ≤1                                                                                                 1
  \>1--5                                                                                             1.23(0.81,1.88)
  \>5--10                                                                                            1.70(1.10,2.62)
  \>10                                                                                               2.55(1.68,3.89)
  **Length of hospital stay (in days)**                                                              
  ≤5                                                                                                 1
  \>5--10                                                                                            2.43(1.86,3.17)
  \>10                                                                                               2.99(2.24,3.99)
  **Blood glucose level (HbA1c)**                                                                    
  \<7%                                                                                               1
  ≥7%                                                                                                2.09(1.67,2.62)
  Unknown                                                                                            1.19(0.69,2.06)
  **Neoplasms (C00-D48)**                                                                            
  No                                                                                                 1
  Yes                                                                                                0.51(0.36,0.70)
  **Endocrine, nutritional and metabolic diseases (E00-E90)**[\*](#t003fn001){ref-type="table-fn"}   
  No                                                                                                 1
  Yes                                                                                                2.24(1.76,2.85)
  **Circulatory system diseases (I00-I99)**                                                          
  No                                                                                                 1
  Yes                                                                                                4.35(3.62,5.23)
  **Skin and subcutaneous tissue diseases (L00-L99)**                                                
  No                                                                                                 1
  Yes                                                                                                1.64(1.04,2.59)
  **Musculoskeletal system and connective tissue diseases (M00-M99)**                                
  No                                                                                                 1
  Yes                                                                                                1.61(1.27,2.03)
  **Pregnancy, childbirth and the puerperium (O00-O99)**                                             
  No                                                                                                 1
  Yes                                                                                                0.06(0.01,0.49)

\*Excludes T2DM

Variables age, sex, education, occupation, marital status, residence, health insurance, smoking, alcohol drinking, duration of T2DM, blood glucose level (HbA1c), length of hospital stay, infectious and parasitic diseases, neoplasms, blood diseases, endocrine diseases, mental and behavioural disorders, nervous system diseases, circulatory system diseases, respiratory system diseases, digestive system diseases, skin diseases, musculoskeletal system diseases, genitourinary system diseases, pregnancy and the puerperium were included.

[Table 4](#pone.0220047.t004){ref-type="table"} shows the sensitivity analyses (multiple logistic regression models)---independent variables with p≤0.20 in simple logistic regressions were included. We found similar results in the sensitivity analyses.

10.1371/journal.pone.0220047.t004

###### Sensitivity analyses (multiple logistic regression models)---independent variables with p≤0.20 in simple logistic regressions were included.
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                                                                                                     Adjusted OR (95% CI)
  -------------------------------------------------------------------------------------------------- ----------------------
  ***Polypharmacy prescription (Yes)***                                                              
  **Age (in years)**                                                                                 
  18--39                                                                                             1
  40--59                                                                                             1.85(1.27,2.69)
  ≥60                                                                                                2.37(1.62,3.47)
  **Duration of T2DM (in years)**                                                                    
  ≤1                                                                                                 1
  \>1--5                                                                                             1.22(0.80,1.87)
  \>5--10                                                                                            1.68(1.09,2.58)
  \>10                                                                                               2.50(1.64,3.80)
  **Length of hospital stay (in days)**                                                              
  ≤5                                                                                                 1
  \>5--10                                                                                            2.44(1.87,3.18)
  \>10                                                                                               3.00(2.25,4.00)
  **Blood glucose level (HbA1c)**                                                                    
  \<7%                                                                                               1
  ≥7%                                                                                                2.10(1.68,2.62)
  Unknown                                                                                            1.18(0.68,2.04)
  **Neoplasms (C00-D48)**                                                                            
  No                                                                                                 1
  Yes                                                                                                0.49(0.35,0.68)
  **Endocrine, nutritional and metabolic diseases (E00-E90)**[\*](#t004fn001){ref-type="table-fn"}   
  No                                                                                                 1
  Yes                                                                                                2.24(1.76,2.85)
  **Circulatory system diseases (I00-I99)**                                                          
  No                                                                                                 1
  Yes                                                                                                4.34(3.61,5.21)
  **Skin and subcutaneous tissue diseases (L00-L99)**                                                
  No                                                                                                 1
  Yes                                                                                                1.63(1.03,2.57)
  **Musculoskeletal system and connective tissue diseases (M00-M99)**                                
  No                                                                                                 1
  Yes                                                                                                1.57(1.24,1.97)
  **Pregnancy, childbirth and the puerperium (O00-O99)**                                             
  No                                                                                                 1
  Yes                                                                                                0.05(0.01,0.44)

\*Excludes T2DM

Variables age, education, occupation, marital status, residence, health insurance, duration of T2DM, blood glucose level (HbA1c), length of hospital stay, neoplasms, endocrine diseases, mental and behavioural disorders, nervous system diseases, circulatory system diseases, respiratory system diseases, skin diseases, musculoskeletal system diseases, genitourinary system diseases, pregnancy and the puerperium were included. (Sex, smoking, alcohol drinking, infectious and parasitic diseases, blood diseases, digestive diseases were excluded.)

Discussion {#sec013}
==========

In our study, around three fourth of T2DM patients were prescribed polypharmacy. Those who were prescribed polypharmacy, the average number of medicines was eight. Globally, similar studies have been conducted in different diabetes populations and settings, during different time periods, using similar or different case definitions of polypharmacy. The prevalence of polypharmacy (≥5 medicines) among T2DM patients in Italy and Brazil was 57% and 85%, respectively \[[@pone.0220047.ref017],[@pone.0220047.ref021]\]. In similar studies conducted among diabetes patients in Brazil and Saudi Arabia, it was 57% and 78%, respectively \[[@pone.0220047.ref016],[@pone.0220047.ref018]\]. 48% of patients with diabetes and hypertension in Canada were prescribed ≥9 medicines \[[@pone.0220047.ref019]\]. The average number of medicines prescribed to T2DM patients in India and Germany was five and 12, respectively \[[@pone.0220047.ref015],[@pone.0220047.ref020]\]. A standardised universally accepted definition of polypharmacy is not available. A recently published systematic review reported that approximately half of the published studies defined polypharmacy as administering ≥5 medicines to an individual. They found a huge variation in the definition of polypharmacy used, which ranged from ≥2 medicines to ≥11 medicines \[[@pone.0220047.ref032]\]. Therefore, in our study, we selected the most commonly used definition of polypharmacy ie, the simultaneous prescription of ≥5 medicines.

In T2DM, the core management strategy is to control blood glucose and prevent or manage vascular complications \[[@pone.0220047.ref027]\]. Similar to our study, in China, the management of uncontrolled blood glucose levels and T2DM complications (if any) are often the two main reasons for hospitalisation of T2DM patients \[[@pone.0220047.ref033]\]. During their stay at the hospital, the management strategy can be different and may involve multiple essential medicines for treating complex and severe conditions. We found that around 80% of T2DM patients were prescribed oral antidiabetic drugs and a high proportion (75%) were prescribed insulin. In China, if the first line of treatment (oral antidiabetic drugs) fails to control the blood glucose levels, insulin (premix or basal) is recommended and sometimes in combination with oral antidiabetic drugs \[[@pone.0220047.ref034]\]. All these increases the complexity of T2DM management and the burden of medicines. Drug-drug interactions can be categorised as pharmacodynamics or pharmacokinetics \[[@pone.0220047.ref035]\]. The risk of a potential drug interaction increases from 13% for two drugs to 82% for ≥7 drugs \[[@pone.0220047.ref036]\]. For example, drugs like sulphonylurea and aspirin have a high tendency to bind with plasma proteins \[[@pone.0220047.ref037],[@pone.0220047.ref038]\]. When these two drugs are administered simultaneously, aspirin can compete with sulphonylurea. Thereafter, aspirin can bind with plasma proteins, displacing sulphonylurea from plasma proteins \[[@pone.0220047.ref038]\]. Due to this, the level of sulphonylurea in plasma can increase, which in turn can increase the risk of hypoglycemia, especially among those T2DM patients with controlled (near normal) blood glucose levels \[[@pone.0220047.ref039]\]. Almost two third of T2DM patients in our study were prescribed β-Hydroxy β-methylglutaryl CoA *(*HMG CoA*)* reductase inhibitors like atorvastatin, lovastatin and simvastatin. One of the severe adverse effects of statins is myopathy. These statins are metabolised by an enzyme, cytochrome P450 3A4 (CYP3A4). Calcium channel blockers like amlodipine are inhibitors of CYP3A4. When these two drugs are administered simultaneously, for example, simvastatin plus amlodipine, amlodipine can increase the level of simvastatin in plasma, which in turn can increase the risk of myopathy \[[@pone.0220047.ref035],[@pone.0220047.ref040]\]. Thus, there is an urgent need to develop, evaluate and implement interventions to support medicines optimisation (and deprescribing) among T2DM patients.

The odds of polypharmacy prescription increased with patients' age in our study, as in studies conducted among diabetes patients in Saudi Arabia and Brazil \[[@pone.0220047.ref016],[@pone.0220047.ref018]\]. Even in studies conducted among the general population in Switzerland and Japan, the prevalence of polypharmacy increased with age \[[@pone.0220047.ref041],[@pone.0220047.ref042]\]. Usually, older patients have more comorbidities and seek care from multiple healthcare providers \[[@pone.0220047.ref043]\], which may increase the chance of polypharmacy. Even after we adjusted for some known comorbidities, age was found to be independently associated with polypharmacy prescription. Due to the natural senescence process of liver and kidneys in older patients, the risk of drug accumulation is more serious \[[@pone.0220047.ref044],[@pone.0220047.ref045]\]. The adverse effect of a drug can be misinterpreted as a sign or symptom of a new disorder and new drugs may be added to the medication list to manage it, which is known as "prescription cascade". This further complicates the matter by increasing the risk of unwanted drug interactions between existing and new drugs and resulting in adverse drug events, especially among older patients who are already on multiple drugs \[[@pone.0220047.ref046]\].

The odds of polypharmacy prescription increased with the duration of T2DM in our study. Similarly, a study conducted among T2DM patients in Italy reported that polypharmacy was associated with ≥5 years duration of T2DM (1.93, 1.38--2.70) \[[@pone.0220047.ref017]\]. In another study conducted among diabetes patients in Brazil, polypharmacy was found to be associated with ≥10 years duration of T2DM (1.64, 1.36--1.98) \[[@pone.0220047.ref016]\]. With the progression of T2DM, the function and mass of β-cells gradually decline \[[@pone.0220047.ref047]\]. In T2DM patients, single antidiabetic drugs like metformin, sulfonylureas or thiazolidinediones cannot control their blood glucose levels for a long period of time and as the disease progresses over time, they will need multiple antidiabetic drugs \[[@pone.0220047.ref047]\]. In addition, the risk of vascular complications increases with the duration of T2DM \[[@pone.0220047.ref048]\] and thus, will require multiple medicines as part of the management strategy.

We found that the odds of polypharmacy prescription increased with the length of hospital stay in T2DM patients. Similarly, a study conducted among older patients in India reported the association between longer length of hospital stay and polypharmacy (3.14, 2.09--4.71 for 10 to \<15 days length of hospital stay; and 5.74, 2.43--13.51 for ≥15 days length of hospital stay) \[[@pone.0220047.ref049]\]. Length of hospital stay is a known indicator of the severity of T2DM, its comorbidities and complications \[[@pone.0220047.ref050]\]. The more complex and severe the case is, the more medicines are required to manage it.

The odds of polypharmacy prescription were higher in those with poor blood glucose level in our study. In T2DM patients with poor blood glucose levels, additional antidiabetic drugs are needed, as is evident from another study conducted among T2DM patients in the USA \[[@pone.0220047.ref051]\]. It should be noted that poor blood glucose levels could be due to comorbidities (eg, other metabolic disorders), requiring additional antidiabetic drugs. In our study, comorbidities were adjusted for in the models.

We found that the average number of comorbidities was five among those who were prescribed polypharmacy. The odds of polypharmacy prescription were higher in those with comorbidities like other endocrine, nutritional and metabolic diseases (such as obesity, hyperuricaemia, hyperlipidaemia and T2DM micro-vascular complications), circulatory system diseases (such as hypertension and T2DM macro-vascular complications like coronary heart disease and stroke), skin and subcutaneous tissue diseases, and musculoskeletal system and connective tissue diseases. Similarly, in a study conducted among T2DM patients in Ireland, those with one and ≥5 chronic illnesses were prescribed three and eight medicines on an average, respectively \[[@pone.0220047.ref052]\]. In another study conducted among T2DM in Italy, polypharmacy was found to be associated with comorbidities, assessed using the Cumulative Illness Rating Scale (CIRS) (1.9, 1.41--2.54 for CIRS ≥2) \[[@pone.0220047.ref017]\]. In a study conducted among diabetes patients in Saudi Arabia, polypharmacy was found to be associated with cardiovascular diseases (2.89, 2.54--3.29), mental health conditions (2.19, 1.74--2.76), respiratory diseases (2.42, 1.92--3.03) and musculoskeletal diseases (3.16, 2.31--4.30) \[[@pone.0220047.ref018]\]. Usually, T2DM patients will have at least one comorbidity and approximately 40% of them will have ≥3 comorbidities \[[@pone.0220047.ref052],[@pone.0220047.ref053]\]. It should be noted that T2DM patients are also prone to skin diseases \[[@pone.0220047.ref054]\]. As mentioned above, there is a high risk of "prescription cascade" in older patients, and itching is one of the known adverse effects of drugs, which in turn will need medicines \[[@pone.0220047.ref055],[@pone.0220047.ref056]\]. One of the prominent clinical symptoms of the musculoskeletal system and connective tissue diseases is the pain, which will also need medicines \[[@pone.0220047.ref057]\].

In this study, the odds of polypharmacy prescription were lower in those with comorbidities like neoplasms and during pregnancy, childbirth and the puerperium. The benign neoplasms do not require any medicine such as uterine leiomyoma, the pituitary tumour with no function and hepatic haemangioma. We found that the odds of polypharmacy prescription were lower in those with malignant neoplasms compared to no tumours ([S1 Table](#pone.0220047.s001){ref-type="supplementary-material"}). It should be noted that patients with malignant neoplasms requiring multiple medicines are primarily treated elsewhere (and not in this tertiary care department). Those admitted to this tertiary care department usually have reduced life expectancy, and the primary management aim is to provide palliative care with minimal medicines \[[@pone.0220047.ref027],[@pone.0220047.ref034]\]. In fact, their blood glucose, blood pressure and lipid targets are relaxed and thus, multiple medicines are avoided \[[@pone.0220047.ref027],[@pone.0220047.ref034]\]. During pregnancy, only insulin is approved for controlling blood glucose levels in China \[[@pone.0220047.ref027],[@pone.0220047.ref034]\]. Similarly, many medicines are not prescribed or used in pregnancy to avoid known and unknown adverse effects on the foetus \[[@pone.0220047.ref058]\].

The study has a number of strengths and weaknesses. As far as we are aware, this was the first study in China to explore polypharmacy prescription among T2DM patients. Our study findings could be taken into consideration in future interventional studies aimed at supporting medicines optimisation (and deprescribing) among these patients. This study was conducted among T2DM patients who were discharged from the tertiary care department and thus, the generalisability of study findings is limited to similar populations and settings. As mentioned before, studies conducted in other diabetes (including T2DM) populations and settings have reported a range of prevalence figures \[[@pone.0220047.ref015]--[@pone.0220047.ref021]\]. In China, studies conducted in community settings have reported a much lower prevalence of polypharmacy (6--18%) \[[@pone.0220047.ref022]--[@pone.0220047.ref024]\]. Our study focused on prescribed western medicines. Data on other important components such as over-the-counter medicines, traditional Chinese medicines and actual usage of medicines were not available in the database and needs further exploration to provide a more complete picture of the issue. Missing data, which could lead to bias, were low in this study. A sample with missing values for the variable was included in the regression analyses. This was a retrospective study, which used an existing computerised medical records database. The primary purpose of the development of this database was clinical and not research and thus, data quality issues (such as accuracy and reliability) of routinely collected data cannot be ignored. However, hospitalised patients, due to disease severity, are usually precisely monitored, and this could have improved the data quality. Recall error could have been a problem with self-reported data (eg, duration of T2DM). The inaccurate measurement of the variable could mean that patients were assigned to the wrong group, which resulted in an incorrect estimation of the association between duration of T2DM and polypharmacy prescription. There is a possibility that our study findings were the outcome of other factors (such as cognitive performance, diet and physical activity) not present in the database and so, not adjusted for in the models \[[@pone.0220047.ref016], [@pone.0220047.ref059]--[@pone.0220047.ref061]\]. Similarly, only the current status of smoking and alcohol drinking was available in the database and the past history was missing. Being a cross-sectional study, it was not possible to assess the causal relationship between different variables and polypharmacy prescription. We suggest conducting a longitudinal study among T2DM patients to evaluate the impact of various factors (these as well as other potential factors) on polypharmacy prescription. In addition, ours was a hospital-based study, and a population-based study might provide a different picture of the issue. The reasons could be different population characteristics, including their disease severity and healthcare-seeking behaviour.

In conclusion, around three fourth of T2DM patients at the tertiary care department were prescribed polypharmacy, and the predictors were identified. The study findings could be taken into consideration in future interventional studies aimed at supporting medicines optimisation (and deprescribing) among these patients.
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